

INSPIREMD, INC.

FORM 8-K (Current report filing)

Filed 02/18/14 for the Period Ending 02/18/14

Address 321 COLUMBUS AVENUE

BOSTON, MA 02116

Telephone (857) 453-6553

CIK 0001433607

Symbol NSPR

SIC Code 3841 - Surgical and Medical Instruments and Apparatus

Industry Medical Equipment & Supplies

Sector Healthcare

Fiscal Year 12/31



UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 18, 2014

InspireMD, Inc.

(Exact name of registrant as specified in its charter)

	Delaware	001-35731	26-2123838			
	(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)			
321 Columbus Avenue						
Boston, Massachusetts			02116			
(Address of principal executive offices)			(Zip Code)			
	Registrant's telephone number, including area code: (857) 453-6553					
(Former name or former address, if changed since last report)						
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:						
	Written communications pursuant to Rule 4	25 under the Securities Act (17 CFR 230.425)				
	Soliciting material pursuant to Rule 14a-12	under the Exchange Act (17 CFR 240.14a-12)				
	Pre-commencement communications pursua	ant to Rule 14d-2(b) under the Exchange Act (17	CFR 240.14d-2(b))			
	Pre-commencement communications pursua	ant to Rule 13e-4 (c) under the Exchange Act (17	CFR 240.13e-4(c))			

Item 8.01 Other Events.

On February 18, 2014, InspireMD, Inc. (the "Company") issued a press release announcing that the Company will release its financial results for the six month period ended December 31, 2013 on February 26, 2014. The Company will also host a conference call to review the Company's financial results and business outlook at 4:30 p.m. Eastern Time on February 26, 2014.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description	
99.1	Press release dated February 18, 2014	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INSPIREMD, INC.

Date: February 18, 2014 By: /s/ Alan Milinazzo

Name: Alan Milinazzo

Title: President and Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description	
99.1	Press release dated February 18, 2014	



InspireMD to Report Financial Results for Six Month Period Ended December 31, 2013 on Wednesday, February 26, 2014

BOSTON, Ma – February 18, 2014 - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will release its financial results for the six month period ended December 31, 2013 on February 26, 2014.

The Company will host a conference call at 4:30 p.m. ET on Wednesday, February 26 th to review the Company's financial results and business outlook. Participants should call (877) 407-0784 (United States) or (201) 689-8560 (International) and request the InspireMD call or provide confirmation code 13576207. A live webcast of the call will also be available on the Investor Relations section of the Company's website at www.inspire-md.com/site_en/for-investors. Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

An archive of the webcast will be available approximately one hour after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.inspire-md.com/site_en/for-investors for a limited time. A dial-in replay of the call will also be available to those interested until March 12, 2014. To access the replay, dial (877) 870-5176 (United States) or (858) 384-5517 (International) and enter code 13576207.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MGuardTM with MicroNetTM technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuardTM) and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

Investor Contacts:

Todd Fromer / Garth Russell KCSA Strategic Communications Phone: 212-896-1215 / 212-896-1250

Email: tfromer@kcsa.com / grussell@kcsa.com

Media Contacts:

Lewis Goldberg / Samantha Wolf KCSA Strategic Communications Phone: 212-896-1216 / 212-896-1220

Email: lgoldberg@kcsa.com / swolf@kcsa.com